Devita, Hellman, and Rosenberg's Cancer

LWBK1006-08 LWW-Govindan-Review December 12, 2011 18:49

Chapter 8•Principles of Medical Oncology 99

Question 8.25. Cyclin-dependent kinases are inhibited by:

A. Bortezomib

B. Cetuximab

C. Flavopiridol

D. Trastuzumab

Question 8.26. All of the following are limitations of the RECIST criteria, EXCEPT:

A. Bone-only disease is difficult to measure.

B. Partial responses are not taken into account.

C. Tumor necrosis after therapy may actually increase the size of a mass.

D. There may be several nonmeasurable sites of tumor involvement.

Question 8.27. Computed tomography contrast perfusion and dynamic-contrast mag-

netic resonance imaging may be useful in evaluating:

A. Response to alkylating agents

B. Response to antiangiogenic agents

C. Degree of tumor necrosis

D. Overall survival

Question 8.28. Which of the following is true regarding the use of time to progression as

an end point in clinical trials?

A. Uses a smaller sample size when compared with using overall survival

as an end point.

B. Not confounded by subsequent therapies.

C. The study can be completed in a shorter amount of time.

D. All of the above.